Prevalência de atipias citológicas e infecção pelo papilomavírus humano de alto risco em mulheres indígenas Panará, povo indígena do Brasil Central

Rodrigues, Douglas; Pereira, Ediléa Dutra; Oliveira, Lavínia Santos de Souza; Speck, Neila Maria de Góis; Gimeno, Suely Godoy Agostinho

doi:10.1590/0102-31l1x00152713

Cited by 1 publication

(1 citation statement)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Indigenous women in Latin America are more vulnerable to cervical cancer than non-indigenous women. The prevalence of precursor lesions is high, cases are diagnosed in advanced stages, incidence and mortality rates are high, and survival is low [1][2][3][4][5][6][7][8][9][10][11][12][13][14]. Despite the variable rates of HPV prevalence, genetic diversity is reported and overlaps with poor knowledge regarding the immunological aspects [2,8,11,13,15].…”

Section: Introductionmentioning

confidence: 99%

Cervical cancer screening in Brazilian Amazon Indigenous women: Towards the intensification of public policies for prevention

Novais,

Coelho,

Machado

et al. 2023

PLoS ONE

View full text Add to dashboard Cite

Background Indigenous women are vulnerable to cervical cancer. Screening is a strategy to reduce the burden of the disease. Objective To evaluate the prevalence profile of cervical cancer screening cytological results in Brazilian indigenous women by age and frequency of tests compared to non-indigenous women. Methods A cross-sectional study evaluating the prevalences of screening test results in indigenous women assisted in the Brazilian Amazon from 2007 to 2019 (3,231 tests), compared to non-indigenous women (698,415 tests). The main outcome was the cytological result. Other variables were frequency, age groups, and population. The frequency was categorized as "1st test", the first test performed by the women in their lifetime, or "screening test," tests from women who had previously participated in screening. Analyzes were based on prevalences by age group and population. We used Prevalence Ratios (PR) and 95% Confidence Intervals for risks and linear regression for trends. Results Data from the 1st test showed a higher prevalence of Low-grade Squamous Intraepithelial Lesion (LSIL) in indigenous women. Peaks were observed in indigenous under 25, 35 to 39, 45 to 49, and 60 to 64. The prevalence of High-grade Squamous Intraepithelial Lesion or more severe (HSIL+) was low in both groups in women younger than 25. The indigenous HSIL+ prevalence curve showed a rapid increase, reaching peaks in women from 25 to 34 years, following a slight decrease and a plateau. In screening tests, HSIL+ was more prevalent in indigenous from 25 to 39 (PR 4.0,2.3;6.8) and 40 to 64 (PR 3.8,1.6;9.0). In indigenous, the PR of HSIL+ results in screening tests over 1st tests showed no screening effect in all age groups. In non-indigenous, there was a significant effect toward protection in the age groups over 25. Conclusion This screening study of indigenous women from diverse ethnicities showed a higher prevalence of cytological LSIL and HSIl+ than in non-indigenous women. The protective screening effect in reducing HSIL+ prevalence was not observed in indigenous.

show abstract